Experimental KRAS blocker tested in advanced cancers – trial halted early

NCT ID NCT06599502

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cetuximab). Only 17 people took part before the trial was stopped early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0022 (a drug that blocks the KRASG12D mutation) and cetuximab (a targeted antibody)
What this could lead to: If successful, this could point toward a new treatment option for cancers with the KRASG12D mutation, like some lung, pancreatic, and colorectal cancers.
What could go wrong: This was a very early (phase I/IIa) trial that was terminated early with only 17 participants, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS COLORECTAL CANCER (CRC) NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

Research Site

Duarte, California, 91010, United States
Research Site

New York, New York, 10016, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Melbourne, 3000, Australia
Research Site

Chūōku, 104-0045, Japan
Research Site

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.